AI scale with tiny teams
An Indian Express piece described an example of an AI‑enabled company valued at $1.8B run by just two people, illustrating that AI can compress headcount in certain software businesses. The article framed this as a cautionary signal about operational brittleness and dependence on third‑party models even as it enables outsized scale (indianexpress.com).
A two-person telehealth company called Medvi is on track for $1.8 billion in 2026 sales after posting $401 million in 2025. (indianexpress.com) The company was built by Matthew Gallagher, 41, who told The New York Times he started Medvi with $20,000 and later hired his younger brother, Elliot, as the only full-time employee besides himself. Medvi sells access to compounded glucagon-like peptide-1, or GLP-1, weight-loss drugs through a telehealth model. (nytimes.com) Gallagher said artificial intelligence handled work that normally requires staff: writing software code, buying digital ads, drafting customer-service replies, and generating marketing material. Medvi also relied on contractors, outside agencies, and partner pharmacies for work that the two brothers did not do themselves. (nytimes.com) The basic idea is simple: large language models are prediction engines for text, images, and code, so one person can use them like a stack of on-demand assistants. OpenAI chief executive Sam Altman said in 2024 that a one-person billion-dollar company would become possible, and Medvi is now being cited as one of the closest real-world examples. (indianexpress.com) This model cuts payroll, but it also shifts risk outward. If the underlying model provider changes pricing, policies, uptime, or safety rules, a tiny company that depends on those tools can lose capacity overnight. (forbes.com) Medvi’s case also shows that “two employees” does not mean “two people touched the business.” Reports on the company say it used contract engineers, account managers, affiliate marketers, pharmacies, and clinical partners, which kept headcount low while pushing key functions outside the firm. (drugdiscoverytrends.com) The company’s speed has drawn scrutiny along with attention. On February 20, 2026, the United States Food and Drug Administration sent Medvi a warning letter saying its website marketed compounded semaglutide and tirzepatide with claims the agency said were false or misleading. (fda.gov) Outside reporting has also raised questions about Medvi ads that used doctors and patients who could not be verified as real. Medvi said on April 8, 2026, that the material came from an affiliate marketing agency and said it had removed or was reviewing the content. (futurism.com, home.medvi.org) The point of the Medvi story is not that every company can run on two people. It is that artificial intelligence can compress headcount in software-heavy businesses while leaving regulation, operations, and reputation as stubbornly human constraints. (indianexpress.com, fda.gov)
